Dr. Fan Zhang, MD

Dr. Zhang practices at Permanente Medical Group Inc in Stockton, California.

Dr. Zhang's NPI, 1619051695, was assigned on October 25, 2006. Dr. Zhang graduated from Sun Yat-Sen University of Medical Science in 1986. Dr. Zhang holds California license A81734.

Dr. Zhang's primary practice is Permanente Medical Group Inc, at 7373 West Ln, Stockton, CA 95210 in San Joaquin County. The practice phone is (209) 476-2000.

Dr. Zhang's primary practice is Permanente Medical Group Inc in Stockton, California. Dr. Zhang is also affiliated with Alaska Native Medical Center. The medical group on file is The Permanente Medical Group, Inc. Dmand AI also links Dr. Zhang to 5 more hospitals and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zhang practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Zhang's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Zhang is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Zhang's licenses on file in 6 states: California, Alaska, Nebraska, Colorado, New York and Texas.

CMS data shows 28 Medicare services from Dr. Zhang across 1 procedure code in 2024, all of them office visits, for 39 Medicare patients. Medicare paid $2,820 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 39 Medicare patients who saw Dr. Zhang in 2024. The largest group is 65 to 74, with 19 patients. 56% of them have tobacco use, and 54% have copd. 72% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zhang's median patient age at 73, with 57% women.

In 2024, Dr. Zhang wrote 368 Medicare Part D claims for 178 patients. 77% of them were for generic drugs. CMS names the drug for 181 of them, across 8 drugs with 11 or more claims each, at $6,589 in total drug cost. In 2023, CMS named 1,292 claims across 39 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Zhang for performance year 2024, reported as part of a group. Dr. Zhang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zhang as offering telehealth.

Dmand AI links 109 papers to Dr. Zhang, published from 2001 to 2025. 2013 was the busiest year, with 9. The most frequent topics are Cell Line, Tumor, Signal Transduction and Gene Expression Regulation, Neoplastic. Dr. Zhang has published most often in Oncogene. Dr. Zhang's most frequent co-authors are Gordon B. Mills, MD, PhD, Shahin Rafii, MD and Ronald G. Crystal, MD.

CMS Open Payments shows 17 general payments to Dr. Zhang from 10 drug and device companies from 2016 to 2024. Grants make up the largest share, 78% of the total. Medtronic USA, Inc. paid the most, $3,750.

Dmand AI lists 1 award for Dr. Zhang, most recently CMS Stage 1 2012 in 2011.

Dr. Zhang graduated from Sun Yat-Sen University of Medical Science in 1986.

Dr. Zhang is in network with 12 carriers, including United Healthcare, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.